ABMD - Abiomed EPS beats by $0.03 revenue in-line

Abiomed (NASDAQ:ABMD): Q3 Non-GAAP EPS of $1.03 beats by $0.03; GAAP EPS of $1.24 beats by $0.22. Revenue of $248.1M (+18.3% Y/Y) in-line. Press Release Worldwide Impella® heart pump product revenue for the quarter totaled $235.8 million, an increase of 18% compared to $199.7 million during the same period of the prior fiscal year. U.S. Impella product revenue for the quarter totaled $189.8 million, an increase of 16% compared to $163.2 million during the same period of the prior fiscal year, with U.S. patient usage of Impella heart pumps up 8%. FY22 Outlook: Abiomed started the fiscal year with a range of $990 million to $1,030 million with growth of 17% - 22% versus prior year. After a strong Q1 and a solid July, the company upgraded guidance to $1,030 million to $1,050 million with growth of 22% - 24%. Given the delta resurgence and the U.S. hospital labor shortages, the company is updating its

For further details see:

Abiomed EPS beats by $0.03, revenue in-line